TOP 5 MOST VIEWED ARTICLES

RECENT COMMENTS

Azmina: In my personal experience, Medical Oncology teams would love to be able to offer patients concurrent [...]   »Read more

Storme Guy: I agree that false promises or prediction are done in a non correct way. Always, medical oncologist [...]   »Read more

Alex: You use EUS for staging only the smaller tumours. What about using endoscopic mucosal resection for [...]   »Read more

dinha: Please write your comment here   »Read more

headcoverings for chemotherapy: I recently came across your blog and have been reading along. I thought I would leave my first c [...]   »Read more

 

Article type: Ace Reporter Award

Keywords: Ioanna Soufleri, ACE Reporter Award, To Vima, chronic disease, stomach cancer, cancerous cells, .

This article has 0 comments

Facebook Twitter Share - Send - Print - Pdf

 

How the hostage-taking of Twist hit the mass media

How the hostage-taking
of Twist hit the mass media

Ioanna Soufleri writes for the Greek daily newspaper To Vima. In a series of articles that jointly won her the 2005 ACE (Awarding Excellence in Cancer) Reporter’s Award, she has shown that progress in cancer can make fascinating reading without resorting to misleading talk of ‘wonder drugs’ and ‘breakthroughs’. Below we reprint a sample of her work.

» Ioanna Soufleri


To read the complete article please click on the pdf icon
 
COMMENTS (0)
When submitted, your comment will be moderated. Messages which may be considered defamatory, which incite hatred or contain foul or abusive language, or are gratuitously offensive, will not be published. Please ensure that your comments are concise and relevant to the topic in question. Off-topic comments and comments without a username will not be published.

ESO reserves the absolute right not to publish comments.
  Name (required)
  E-mail (will not be published) (required)
  Captcha code (required)

CancerWorld invites you to visit:

 
CancerWorld is a pioneering initiative of the European School of Oncology financially supported through Sharing Progress in Cancer Care, a collaborative programme between ESO and Amgen, Celgene, Eisai, Eli Lilly, Genomic Health, GlaxoSmithKline, Merck Serono, Novartis, Roche and Sanofi Aventis.